CStone Pharmaceuticals (HKSE:02616) Cash And Cash Equivalents : HK$0.0 Mil (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals Cash And Cash Equivalents?

CStone Pharmaceuticals's quarterly cash and cash equivalents declined from Jun. 2022 (HK$857.41 Mil) to Dec. 2022 (HK$623.89 Mil) but then stayed the same from Dec. 2022 (HK$623.89 Mil) to Jun. 2023 (HK$0.00 Mil).

CStone Pharmaceuticals's annual cash and cash equivalents declined from Dec. 2021 (HK$909.44 Mil) to Dec. 2022 (HK$623.89 Mil) but then increased from Dec. 2022 (HK$623.89 Mil) to Dec. 2023 (HK$1,090.14 Mil).

CStone Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for CStone Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CStone Pharmaceuticals Cash And Cash Equivalents Chart

CStone Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

1,253.44

3,585.40

909.44

623.89

1,090.14

CStone Pharmaceuticals Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial									909.44	857.41	623.89	-	1,090.14

CStone Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

CStone Pharmaceuticals (HKSE:02616) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

CStone Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

CStone Pharmaceuticals (HKSE:02616) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (HKSE:02616) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

CSPHF:USA PH4:Germany

Address

218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123

Website

https://www.cstonepharma.com

CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

Executives

Su Zhou Gong Ye Yuan Qu Zheng Ze Yuan Shi Chuang Ye Tou Zi Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Gong Ye Yuan Qu Zheng Ze Ji Ming Gu Quan Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Zheng Ze Jian Kang Chuang Ye Tou Zi Guan Li Zhong Xin You Xian He Huo	2501 Other
Su Zhou Gong Ye Yuan Qu Yuan He Yuan Dian Chuang Ye Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Guan Wei Hui	2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Jing Ji Fa Zhan You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Yuan He Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Fei Jianjiang	2201 Interest of corporation controlled by you
Wuxi Healthcare Ventures Ii, L.p.	2101 Beneficial owner
Wuxi Healthcare Management, Llc	2201 Interest of corporation controlled by you
Morgan Stanley	2201 Interest of corporation controlled by you
Gic Private Limited	2102 Investment manager
Jiang Frank Ningjun	2307 Founder of a discretionary trust who can infl
Graceful Beauty Limited	2101 Beneficial owner
Boyu Capital Holdings Ltd.	2201 Interest of corporation controlled by you

CStone Pharmaceuticals (HKSE:02616) Headlines

No Headlines